The two generic drugmakers hit back at the FTC's efforts to convince the court not to use the immunity to dismiss the case. Par and Paddock, backed by fellow defendant AbbVie Products LLC, maintain that their Hatch-Waxman Act settlement over testosterone replacement treatment Androgel qualified for the immunity because a federal...